{"downloaded": true, "htmlmade": false, "full": {"id": "32914362", "source": "MED", "pmid": "32914362", "pmcid": "PMC7483040", "fullTextIdList": {"fullTextId": "PMC7483040"}, "doi": "10.1007/s13311-020-00920-8", "title": "Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism.", "authorString": "Schneider SA, Hizli B, Alcalay RN.", "authorList": {"author": [{"fullName": "Schneider SA", "firstName": "Susanne A", "lastName": "Schneider", "initials": "SA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Neurology, Ludwig-Maximilians-University of M\u00fcnchen, Marchioninistr. 15, 81377, Munich, Germany. susanne.schneider@med.uni-muenchen.de."}}}, {"fullName": "Hizli B", "firstName": "Baccara", "lastName": "Hizli", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Neurology, Ludwig-Maximilians-University of M\u00fcnchen, Marchioninistr. 15, 81377, Munich, Germany."}}}, {"fullName": "Alcalay RN", "firstName": "Roy N", "lastName": "Alcalay", "initials": "RN", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Neurology, Columbia University Irving Medical Center, New York, NY, USA. rna2104@cumc.columbia.edu."}}}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "4", "volume": "17", "journalIssueId": "3103924", "dateOfPublication": "2020 Oct", "monthOfPublication": "10", "yearOfPublication": "2020", "printPublicationDate": "2020-10-01", "journal": {"title": "Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics", "ISOAbbreviation": "Neurotherapeutics", "medlineAbbreviation": "Neurotherapeutics", "NLMid": "101290381", "ISSN": "1933-7213", "ESSN": "1878-7479"}}, "pubYear": "2020", "pageInfo": "1378-1392", "abstractText": "In recent years, a precision medicine approach, which customizes medical treatments based on patients' individual profiles and incorporates variability in genes, the environment, and lifestyle, has transformed medical care in numerous medical fields, most notably oncology. Applying a similar approach to Parkinson's disease (PD) may promote the development of disease-modifying agents that could help slow progression or possibly even avert disease development in a subset of at-risk individuals. The urgent need for such trials partially stems from the negative results of clinical trials where interventions treat all PD patients as a single homogenous group. Here, we review the current obstacles towards the development of precision interventions in PD. We also review and discuss the clinical trials that target genetic forms of PD, i.e., GBA-associated and LRRK2-associated PD.", "affiliation": "Department of Neurology, Ludwig-Maximilians-University of M\u00fcnchen, Marchioninistr. 15, 81377, Munich, Germany. susanne.schneider@med.uni-muenchen.de.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print", "pubTypeList": {"pubType": ["Research Support, Non-U.S. Gov't", "review-article", "Review", "Research Support, U.S. Gov't, Non-P.H.S.", "Journal Article", "Research Support, N.I.H., Extramural"]}, "keywordList": {"keyword": ["Clinical Trial", "Kinase Inhibitor", "Lrrk2", "ambroxol", "Gba", "Snca", "Small Molecule Compounds", "Genetic Parkinson\u2019s Disease", "Torc1 Inhibitor", "Venglustat"]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1007/s13311-020-00920-8"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7483040"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7483040?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "2", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCreation": "2020-09-11", "firstIndexDate": "2020-09-12", "fullTextReceivedDate": "2021-02-10", "dateOfRevision": "2021-02-18", "firstPublicationDate": "2020-10-01"}, "htmllinks": "https://europepmc.org/articles/PMC7483040", "abstract": "In recent years, a precision medicine approach, which customizes medical treatments based on patients' individual profiles and incorporates variability in genes, the environment, and lifestyle, has transformed medical care in numerous medical fields, most notably oncology. Applying a similar approach to Parkinson's disease (PD) may promote the development of disease-modifying agents that could help slow progression or possibly even avert disease development in a subset of at-risk individuals. The urgent need for such trials partially stems from the negative results of clinical trials where interventions treat all PD patients as a single homogenous group. Here, we review the current obstacles towards the development of precision interventions in PD. We also review and discuss the clinical trials that target genetic forms of PD, i.e., GBA-associated and LRRK2-associated PD.", "Keywords": ["Clinical Trial", "Kinase Inhibitor", "Lrrk2", "ambroxol", "Gba", "Snca", "Small Molecule Compounds", "Genetic Parkinson\u2019s Disease", "Torc1 Inhibitor", "Venglustat"], "pdflinks": "https://europepmc.org/articles/PMC7483040?pdf=render", "journaltitle": "Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics", "authorinfo": ["Schneider SA", "Hizli B", "Alcalay RN"], "title": "Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism."}